Who is on it, and how far along Every drug ChEMBL records acting on TLR8, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Phase 27 Resiquimod Resiquimod SponsorSURGE Therapeutics ModalitySmall molecule ActionAgonist Open trials6 Enpatoran Enpatoran SponsorMerck KGaA ModalitySmall molecule ActionAntagonist Open trials4 Telratolimod Telratolimod SponsorMedImmune LLC ModalitySmall molecule ActionAgonist Open trials4 Afimetoran Afimetoran SponsorBeeline Medicines Corporation ModalitySmall molecule ActionInhibitor Open trials2 Bazlitoran Bazlitoran SponsorIdera Pharmaceuticals ModalityOther ActionAntagonist Open trials0 Motolimod Motolimod SponsorBristol-Myers Squibb ModalitySmall molecule ActionAgonist Open trials0 Selgantolimod Selgantolimod SponsorGilead Sciences ModalitySmall molecule ActionAgonist Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 7 act as: Toll-like receptor 8 agonist; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus Afimetoran Phase 2 / Phase 3 Recruiting Beeline Medicines Corporation Oct 19, 2026 A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Enpatoran Phase 3 Recruiting EMD Serono Research & Development Institute, Inc. Sep 25, 2026 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) Enpatoran Phase 3 Recruiting EMD Serono Research & Development Institute, Inc. Jan 21, 2026 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease Enpatoran Phase 3 Recruiting EMD Serono Research & Development Institute, Inc. Jan 12, 2026 Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) Resiquimod Phase 1 / Phase 2 Not yet recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences Dec 29, 2025 HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors Resiquimod Early phase 1 Recruiting HighField Biopharmaceuticals Corporation Feb 12, 2025 Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health Telratolimod Phase 1 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) Jan 28, 2025 Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected Telratolimod Phase 1 Not yet recruiting HIV Vaccine Trials Network Sep 26, 2024 Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848) Resiquimod Not applicable Recruiting Akhilesh Jha Jul 5, 2024 Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy Resiquimod Phase 1 Recruiting SURGE Therapeutics Jun 10, 2024 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. Telratolimod Phase 1 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) Mar 27, 2024 Nasal Immune Challenge Study Resiquimod Not applicable Active, not recruiting Cambridge University Hospitals NHS Foundation Trust Sep 1, 2023 Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV Telratolimod Phase 1 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) Jun 15, 2023 A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer Resiquimod Phase 1 / Phase 2 Recruiting SURGE Therapeutics Feb 2, 2023 The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) Enpatoran Phase 2 Active, not recruiting Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Sep 14, 2022 A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Afimetoran Phase 2 Active, not recruiting Beeline Medicines Corporation May 20, 2021
Diseases most associated with it Open Targets association score, 0 to 1; all associations Immunodeficiency 98 with autoinflammation, X-linked 0.74 Immunodeficiency 98 with autoinflammation, X-linked Value0.74 Osteoarthritis 0.42 Osteoarthritis Value0.42 Open Autoimmune hemolytic anemia 0.38 Autoimmune hemolytic anemia Value0.38 Open Systemic autoinflammation 0.37 Systemic autoinflammation Value0.37 Lupus erythematosus 0.33 Lupus erythematosus Value0.33 Open Autoimmune disorder of central nervous system 0.17 Autoimmune disorder of central nervous system Value0.17 Systemic lupus erythematosus 0.12 Systemic lupus erythematosus Value0.12 Open Neoplasm 0.12 Neoplasm Value0.12 Chronic hepatitis B virus infection 0.11 Chronic hepatitis B virus infection Value0.11 Hepatitis B virus infection 0.11 Hepatitis B virus infection Value0.11 Common wart 0.11 Common wart Value0.11 Primary cutaneous T-cell non-Hodgkin lymphoma 0.11 Primary cutaneous T-cell non-Hodgkin lymphoma Value0.11 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5805 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9NR97 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets